Healthcare investing has felt like walking through quicksand this year.
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health advances with Aetna margin recovery, digital investments and cost savings, making it the stronger healthcare bet over Elevance.
CVS Health's Q2 Health Services revenues climb 10%. Yet, AOI slips as cost pressures and Oak Street's rising MBR ail.
'Mad Money' host Jim Cramer takes a look at CVS and what is driving the stock up.
CVS Health's Pharmacy & Consumer Wellness unit posts double-digit revenue gains despite ongoing reimbursement headwinds.
StoneCo, CVS, Integer Holdings and USANA emerge as attractive value stocks with low cash-flow ratios and solid growth outlooks.
StoneCo, CVS Health, KT, KB Financial and USANA Health stand out as undervalued picks with low P/B ratios and solid growth prospects.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.